Pitolisant Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Taletrectinib is a Small molecule drug targeting NTRK x ROS1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Berotralstat Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Ipilimumab is a Monoclonal antibody targeting CTLA4, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Daridorexant hydrochloride is a Small molecule drug targeting OX1R x OX2R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.

Avelumab is a Monoclonal antibody targeting PDL1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Opelconazole: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Remternetug is a Monoclonal antibody targeting APP, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Esketamine Hydrochloride is a Small molecule drug targeting NMDA receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.

Sacubitril is a Small molecule drug targeting CD10, at Pending. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Masitinib mesylate is a Small molecule drug targeting LYN x PDGFRα x PDGFRβ x c-Kit, at Phase 3. This 2026 report reviews clinical evidence, IP, deals.

Sulbactam sodium is a Small molecule drug targeting β-lactamase, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.